These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6440278)

  • 21. Comparison of the in vivo survival of human factor VIII with and without von Willebrand factor in the hemophilic dog.
    Fay PJ; Cavallaro C; Marder VJ; Pancham N; Fournel MA; Schroeder DD
    Thromb Res; 1986 Feb; 41(3):425-9. PubMed ID: 3085273
    [No Abstract]   [Full Text] [Related]  

  • 22. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
    Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
    Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
    Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
    Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor VIII (antihemophilic globulin).
    Aronson DL
    Semin Thromb Hemost; 1979; 6(1):12-27. PubMed ID: 390712
    [No Abstract]   [Full Text] [Related]  

  • 26. Report of a clinical trial of a Canadian preparation of antihemophilic factor.
    Magnin AA; Johnson SE
    Can Med Assoc J; 1979 Aug; 121(4):422-4, 427. PubMed ID: 466616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid correction of AHF deficiency by antihemophilic factor-method four, with special reference to inhibitors.
    Shanbrom E
    Bibl Haematol; 1970; 34():52-9. PubMed ID: 5436353
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
    Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
    J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Arkin S; Rose E; Forster A; Aledort LM
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of D.D.A.V.P. on the survival of factor VIII in severe haemophiliacs.
    McLellan DS; Knight S; McLellan HG; Wassef M; Aronstam A
    Thromb Res; 1985 Oct; 40(1):113-9. PubMed ID: 3937282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII products and inhibitors in severe hemophilia A.
    Iorio A; Skinner MW; Makris M
    N Engl J Med; 2013 Apr; 368(15):1456. PubMed ID: 23574132
    [No Abstract]   [Full Text] [Related]  

  • 33. Factor VIII products and inhibitors in severe hemophilia A.
    van den Berg HM; Gouw SC; van der Bom JG
    N Engl J Med; 2013 Apr; 368(15):1457. PubMed ID: 23574131
    [No Abstract]   [Full Text] [Related]  

  • 34. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute promyelocytic leukemia in a patient with hemophilia. Evidence for rapid consumption of clotting factors.
    Green D
    Thromb Diath Haemorrh; 1972 Jul; 27(3):516-22. PubMed ID: 4514294
    [No Abstract]   [Full Text] [Related]  

  • 36. Lack of response to commercial factor VIII concentrate in hemophilia A.
    Rodgers GM; Ford MH
    Am J Hematol; 1991 Aug; 37(4):288. PubMed ID: 1907098
    [No Abstract]   [Full Text] [Related]  

  • 37. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.
    Arruda VR
    J Thromb Haemost; 2006 Jun; 4(6):1215-7. PubMed ID: 16706962
    [No Abstract]   [Full Text] [Related]  

  • 38. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
    Toolis F; McKay G; Prowse CV
    Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII concentrate available for treatment of classical hemophilia.
    Jewett WR
    Ann N Y Acad Sci; 1975 Jan; 240():188-90. PubMed ID: 1053863
    [No Abstract]   [Full Text] [Related]  

  • 40. Porcine factor VIII therapy in patients with factor VIII inhibitors.
    Hay C; Lozier JN
    Adv Exp Med Biol; 1995; 386():143-51. PubMed ID: 8851022
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.